Corporate Profile

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious diseases. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

INVESTOR HIGHLIGHTS
Corporate Mission

Corporate Mission

Defining our Purpose
Investor Presentation

Investor Presentation

Explore our investor deck
Our Pipeline

Our Pipeline

Explore our pipeline

Event Calendar

View All Events

Jan 14, 2025 1:30 PM PST

43rd Annual J.P. Morgan Healthcare Conference
Click here for webcast
Latest News
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Jan 17, 2025
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Jan 15, 2025
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
Jan 10, 2025
More News
Stock Quote

2025年 1月 17日 6:02 PM EST

Jan 17, 2025 6:02 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2025年 1月 17日 6:02 PM EST

Jan 17, 2025 6:02 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2025年 1月 17日 6:02 PM EST

Jan 17, 2025 6:02 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2025年 1月 17日 6:02 PM EST

Jan 17, 2025 6:02 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

Minimum 15 minutes delayed.
Source: LSEG


Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).

Investor & Media Contacts

Woman looking at phone

Investor Inquiries

Christine Chiou, SVP, Head of Investor Relations
+1 (917) 886-6929
christine.chiou1@zailaboratory.com


Lina Zhang, VP, Corporate Strategy and Capital Markets
lina.zhang@zailaboratory.com

Video Camera

Media Inquiries
Shaun Maccoun, Executive Director, Global Communications
+1 (415) 317-7255
shaun.maccoun@zailaboratory.com
 
Xiaoyu Chen, Executive Director, Regional Communications
xiaoyu.chen@zailaboratory.com